RecruitingNCT06748365
Serum Ferritin and Prognosis of DKA
Role of Ferritin in the Clinical Presentation and Short-Term Prognosis of Diabetic Ketoacidosis
Sponsor
Sohag University
Enrollment
100 participants
Start Date
Jan 1, 2025
Study Type
OBSERVATIONAL
Conditions
Summary
the aim of this study is to: evaluate the association between serum ferritin levels and the clinical presentation and short-term prognosis of patients with DKA. Specifically, the correlation between its level and the severity of DKA at presentation and determine its prognostic value in predicting short-term outcomes.
Eligibility
Min Age: 18 Years
Inclusion Criteria5
- \-
- All patients with DKA :
- Adult Aged 18 years old or older .
- Type 1 DM , type 2 DM
- Diagnosis of DKA based on the American Diabetes Association criteria: blood glucose >250 mg/dL, arterial pH <7.3, serum bicarbonate <18 mEq/L,
Exclusion Criteria9
- Patients age less than 18 years old
- Iron deficiency anemia and iron overload
- Chronic Inflammatory Diseases: Conditions such as rheumatoid arthritis, systemic lupus erythematosus, and inflammatory bowel disease
- Acute and chronic infections, including bacterial, viral, and fungal infections
- Pt presented with other acute complication (MI,stroke)
- CKD patients
- Patients with chronic liver diseases
- Patients with malignancy
- Pregnant women.
Interested in this trial?
Get notified about updates and connect with the research team.
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT06748365
Related Trials
Biomarkers of Acute Organ Injury in Pediatric Newly Diagnosed Type 1 Diabetes
NCT074838791 location
Phase 1 Trial of Arginine Hydrochloride for the Management of Diabetic Ketoacidosis in Type 2 Diabetes
NCT071676931 location
Clinical and Biological Signs of Dapagliflozin Overdose in ICU Patients With Metformin Poisoning
NCT071930691 location
Balanced Multi-Electrolyte Solution Versus Saline Trial for Diabetic KetoAcidosis
NCT0575227921 locations
REAMBERIN® 1.5% in Rehydration Therapy of Diabetic Ketoacidosis
NCT069554163 locations